Publication
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.
Tzvika Porges, Tsofia Levi, Eldad J Dann, Shlomzion Aumann, Ronit Gurion, Shira Buchrits, Chava Perry, Roy Vitkon, Itai Levi, Ellie Ilan, Abraham Avigdor, Ronit Marcus, Reut Harel, Nizar Lahham, May Basood, Kalman Filanovsky, Najib Dally, Gilad Itchaki, Nadav Sarid, Noam Benyamini, Sharon Ben Barouch, Tamar Tadmor, Orit Sofer, Mohamad Aboeid, Ariela Strulovici, Alli Othman, Meirav Kedmi
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Advanced-stage classical Hodgkin lymphoma (cHL) has been traditionally treated with effective chemotherapy regimens, albeit some associated with substantial toxicity. The recently introduced brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) regimen…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerHodgkin Lymphomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available